Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.017 ◽

2021 ◽

Vol 157 ◽

pp. 259-267

Author(s):

Nicholas Spetsieris ◽

Myrto Boukovala ◽

Ioannis Alafis ◽

John Davis ◽

Amado Zurita ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate

Download Full-text

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Case Medical Research ◽

10.31525/ct1-nct04262154 ◽

2020 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Abiraterone Acetate ◽

Newly Diagnosed ◽

Hormone Sensitive

Download Full-text

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717999366.793474668 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Antitumour Activity ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732006685.793538242 ◽

2017 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation

Download Full-text

A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Current Pharmaceutical Analysis ◽

10.2174/1573412913666170213152002 ◽

2018 ◽

Vol 14 (3) ◽

pp. 233-238 ◽

Author(s):

Juana Rodriguez ◽

Gregorio Castaneda ◽

Isabel Lizcano ◽

Jose C. Villa

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Fluorescence Method ◽

Castration Resistant Prostate Cancer ◽

Serum Samples ◽

Castration Resistant ◽

Urine And Serum

Download Full-text

Design and release kinetics of liposomes containing abiraterone acetate for treatment of prostate cancer

Sensors International ◽

10.1016/j.sintl.2020.100077 ◽

2021 ◽

Vol 2 ◽

pp. 100077

Author(s):

Sudipta Das ◽

Arnab Samanta ◽

Shouvik Mondal ◽

Debatri Roy ◽

Amit Kumar Nayak

Keyword(s):

Prostate Cancer ◽

Release Kinetics ◽

Abiraterone Acetate ◽

Download Full-text

Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer

Expert Review of Precision Medicine and Drug Development ◽

10.1080/23808993.2021.1863781 ◽

2020 ◽

pp. 1-9

Author(s):

Jürgen E Gschwend ◽

Kurt Miller

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Hormone Sensitive

Download Full-text

Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2021.1888704 ◽

2021 ◽

Vol 37 (4) ◽

pp. 635-642

Author(s):

Stephen J. Freedland ◽

Sophia Li ◽

Dominic Pilon ◽

Rachel H. Bhak ◽

Sahil Narkhede ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Psa Progression

Download Full-text

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Molecular Oncology ◽

10.1002/1878-0261.12933 ◽

2021 ◽

Author(s):

E. Boerrigter ◽

G.E. Benoist ◽

I.M. van Oort ◽

G.W. Verhaegh ◽

O. van Hooij ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Marker ◽

Liquid Biopsy ◽

Progression Free Survival ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Free Survival ◽

Prednisone Treatment ◽

Castration Resistant

Download Full-text